載入中
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.
前收盤價
US$17.83
+US$0.13 · +0.73%
盤前
US$17.20
−US$0.63 · -3.53%
10月15日 上午4:01 ET
盤中時間採用ET。市場資料可能有所延遲。
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.
日內區間
目前US$17.83
52週區間
目前US$17.83
盤中時間採用ET。市場資料可能有所延遲。
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.
日內區間
目前US$17.83
52週區間
目前US$17.83
報告持有此股票曝險的交易所交易基金。
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED
T. Rowe Price Biotech ETFTDNA
T. Rowe Price Small Cap ETFTSEEAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
